Close Menu

NEW YORK (GenomeWeb) – Researchers from the University of Montreal have developed a proteogenomic approach to identify tumor-specific antigens for use in cancer immunotherapies.

Tumor-specific antigens (TSAs) help the immune system respond to cancer, and cancer immunotherapies may target them to boost that response. But according to Montreal's Claude Perreault and his colleagues, approaches for uncovering TSAs have been beset by false-positive findings or meager yield, and have focused on mutated TSAs rather than aberrantly expressed TSAs.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
08
Sponsored by
Qiagen

Cancer is a complex and heterogeneous disease requiring patient-specific molecular analysis to support treatment decisions.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.